Women’s hesitation to seek menopause treatment risks long-term health 

Many women silently endure the uncomfortable symptoms of menopause, often viewing it as a natural part of life. However, according to Professor Kim Mee-ran, an obstetrics and gynecology expert at the Catholic University of Korea Seoul St. Mary’s Hospital, this may cause them to miss the crucial window for optimal treatment.

“The best time to start treatment is during the menopausal transition—when early symptoms first appear or shortly after menopause begins,” Professor Kim said during a media session hosted by Organon Korea on Monday.

For most, this transition is marked by symptoms such as hot flashes, mood swings, brain fog, and changes in sleep and sexual function. However, this transition, typically occurring between ages 45 and 55, is rarely discussed in Korean society—or even at the doctor’s office. 

A recent survey showed that 80 to 90 percent of Korean women aged 40 to 69 reported experiencing these symptoms, but only three in 10 sought medical treatment. 

Menopause symptoms often follow a pattern, Professor Kim explained, beginning with hot flashes and emotional changes, progressing to urinary and genital symptoms, and ultimately increasing the risks of osteoporosis, cardiovascular disease, and cognitive decline. The decline in estrogen—which happens far more abruptly in women than the gradual hormonal changes seen in men—can leave one in three women susceptible to osteoporosis.

“Many women opt for supplements when menopause hits,” Professor Kim said, “when what’s really needed is structured and professional health care.” She urged women to consider hormone therapy early, ideally around the onset of symptoms, noting that it can significantly relieve discomfort and prevent osteoporosis.

However, lingering fears about cancer risks keep many from seeking hormone therapy. This hesitation traces back to the 2002 Women’s Health Initiative (WHI) study, which reported a slight increase in breast cancer risk with hormone use (8 cases per 10,000 women annually). While some cardiovascular risks were also noted, these primarily affected women who began therapy later in life or had pre-existing health conditions.

“To get the most out of hormone therapy, it’s recommended that women start within 10 years of menopause or before the age of 60,” said Professor Kim. 

For those concerned with breast cancer risks, Professor Kim pointed to Livial (ingredient: tibolone), a selective tissue estrogenic activity regulator (STEAR) that’s been available in Korea since 1992. “Tibolone reduces osteoporosis risk and alleviates hot flashes without significantly raising breast cancer risk,” she said. With selective estrogenic, progestogenic, and androgenic effects, Professor Kim added that it offers a balanced approach, targeting specific tissues like bone and reproductive organs while limiting estrogen action in breast and endometrial tissue.